5,244 Shares in Gilead Sciences, Inc. $GILD Purchased by Compass Financial Management LLC

Compass Financial Management LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 5,244 shares of the biopharmaceutical company’s stock, valued at approximately $671,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Gilead Sciences during the second quarter valued at approximately $15,393,785,000. Norges Bank purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $2,617,152,000. Deutsche Bank AG bought a new stake in Gilead Sciences during the 2nd quarter valued at approximately $918,387,000. Boston Partners bought a new stake in Gilead Sciences during the 4th quarter valued at approximately $517,808,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Gilead Sciences in the 2nd quarter valued at approximately $398,905,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $137.64, for a total value of $3,853,920.00. Following the completion of the transaction, the insider owned 118,234 shares of the company’s stock, valued at $16,273,727.76. This represents a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $138.36, for a total transaction of $415,080.00. Following the transaction, the chief financial officer owned 165,646 shares of the company’s stock, valued at approximately $22,918,780.56. This represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 87,000 shares of company stock worth $11,562,960. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $146.12 on Monday. The firm has a market capitalization of $181.18 billion, a PE ratio of -54.73 and a beta of 0.32. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29. The business’s 50 day moving average is $131.97 and its 200-day moving average is $136.55.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.Gilead Sciences’s revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.01 earnings per share. Sell-side analysts predict that Gilead Sciences, Inc. will post -0.51 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio is currently -122.85%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Needham & Company LLC reiterated a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. HSBC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $133.00 to $155.00 in a research note on Monday, July 6th. Rothschild & Co Redburn dropped their target price on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Morgan Stanley cut their target price on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a research note on Monday, July 27th. Finally, Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Twenty-four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $158.04.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.